Prenylcysteine oxidase 1, an emerging player in atherosclerosis

• DOI: 10.1038/s42003-021-02630-z
• Publication Date: 2021-09-21T10:21:27Z
• Authors: C. Banfi; R. Baetta; S. S. Barbieri; M. Brioschi; A. Guarino; S. Ghilardi; L. Sandrini; S. Eligini; G. Polvani; O. Bergman; P. Eriksson; E. Tremoli
• Keywords: Adult; Inflammation; Male; QH301-705.5; Middle Aged; Atherosclerosis; Article; Carbon-Sulfur Lyases; Mice; Oxidative Stress; 03 medical and health sciences; Prenylcisteine Oxidase 1; atherosclerosis;; Platelet Adhesiveness; 0302 clinical medicine; Animals; Humans; Female; Biology (General); Aged

AbstractThe research into the pathophysiology of atherosclerosis has considerably increased our understanding of the disease complexity, but still many questions remain unanswered, both mechanistically and pharmacologically. Here, we provided evidence that the pro-oxidant enzyme Prenylcysteine Oxidase 1 (PCYOX1), in the human atherosclerotic lesions, is both synthesized locally and transported within the subintimal space by proatherogenic lipoproteins accumulating in the arterial wall during atherogenesis. Further, Pcyox1 deficiency in Apoe-/- mice retards atheroprogression, is associated with decreased features of lesion vulnerability and lower levels of lipid peroxidation, reduces plasma lipid levels and inflammation. PCYOX1 silencing in vitro affects the cellular proteome by influencing multiple functions related to inflammation, oxidative stress, and platelet adhesion. Collectively, these findings identify the pro-oxidant enzyme PCYOX1 as an emerging player in atherogenesis and, therefore, understanding the biology and mechanisms of all functions of this unique enzyme is likely to provide additional therapeutic opportunities in addressing atherosclerosis.